Pfizer launches new cost savings program on TrumpRx to lower drug costs for Americans

Pfizer has recently announced the launch of its program on TrumpRx, to make innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices.

“For far too long, Americans have shouldered a disproportionate share of the global cost of innovation to help develop breakthroughs for the entire world,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “As the first pharmaceutical company to support President Trump in addressing this imbalance, we’re proud to continue to work with the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation.”

Note that through the TrumpRx platform, uninsured or insured American patients who choose to self-pay outside of insurance will be offered savings that range as high as 85%, and on average 50%, for the large majority of Pfizer’s primary care treatments and select specialty brands. This allows American consumers to choose what best fits their needs without hassle. More than 100 million patients are impacted by diseases these medicines treat, such as migraines, rheumatoid arthritis, menopause, atopic dermatitis, overactive bladder – and those patients will now have access to significantly discounted medicines.

---

---

Related Topics and Keywords

Pfizer, TrumpRx